FDA approves BMS’s Opdualag for metastatic or unresectable
WEBMar 23, 2022 · Bristol Myers Squibb (BMS) has announced that Opdualag (nivolumab and relatlimab-rmbw) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult and paediatric patients aged 12 years or older with metastatic melanoma or melanoma which cannot be treated with …
PM Society’s Digital Awards - PMLiVE
WEBApr 21, 2022 · 2022 marks the 13th year of the PM Society’s Digital Awards where we recognise the best in digital creativity, innovation, and effectiveness from across the healthcare industry. We pride ourselves in highlighting the best programmes, tools and campaigns across a broad range of digital activities. …
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBBayer presents positive results for Kerendia in late-stage heart failure study. Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn. Bayer and NextRNA Therapeutics enter oncology partnership worth $547m. J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn.
Eli Lilly to make bebtelovimab commercially available to US states …
WEBAug 4, 2022 · Eli Lilly has made plans to make its COVID-19 antibody drug, bebtelovimab, commercially available to US states, as well as hospitals and other healthcare providers from August, the company announced. The company said it would make bebtelovimab commercially available through a sole distributor beginning the …
AstraZeneca unveils plans for new US R&D centre - PMLiVE
WEBApr 29, 2022 · AstraZeneca (AZ) has revealed plans to open a new US life sciences and innovation site in Cambridge, Massachusetts. The new facility will serve as both a strategic R&D centre for AZ and as Alexion’s new corporate headquarters. Alexion, one of AZ’s subsidiaries, was acquired by the company in July 2021. The …
Pfizer’s pentavalent meningococcal vaccine granted FDA approval
WEBOct 23, 2023 · Pfizer’s Penbraya has been approved by the US Food and Drug Administration (FDA) as the first pentavalent vaccine that provides protection against the five most common serogroups causing meningococcal disease in individuals aged ten to 25 years. Meningococcal disease is an uncommon but serious illness that can lead to death within 24 hours ...
AZ showcases data for next-generation PARP inhibitor AZD5305
WEBApr 12, 2021 · Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer,”said Susan Galbraith, senior vice president and head of research and early development, oncology R&D at …
2023 PM Society Awards – winners announced - PMLiVE
WEBMar 20, 2023 · 21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board. The PM Society’s 37th annual awards was held on 17 March 2023 at the JW Marriott Grosvenor House London when the industry came together to celebrate the best creative communications in pharma and healthcare. PM Society Co-Chair Caroline Benson kicked off the ...
GSK and CureVac to advance mRNA COVID-19 and flu vaccine
WEBJan 9, 2023 · GSK and CureVac will be advancing their jointly developed mRNA COVID-19 and flu vaccine candidates to the next stage of clinical testing after announcing positive preliminary results from early stage trials. The tested vaccine candidates produced promising immunogenicity and reactogenicity profiles in ongoing phase 1 clinical programmes for ...
Navigating engagement and remote working during the pandemic
WEBSep 22, 2020 · Engaging and motivating employees is not a new topic for leaders in medical communications. Neither is flexible or remote working. The coronavirus pandemic has caused many assumptions about working practices to be challenged, and while it has been devastating to see the impact for many organisations, we have also seen others respond with resilience and commitment.
Skip to content